Skip to Content
COVID-19 Response and Update

Parkinson’s Disease

Parkinson’s disease is the fastest growing neurological disorder worldwide, affecting over 1.1 million people in the U.S.

Parkinson’s disease (PD) is a progressive disorder of the central nervous system resulting from a loss of dopamine-producing brain cells that affect movement. It’s characterized by slowness, stiffness, resting tremor, speech changes, impaired balance, and potentially nonmotor symptoms like anxiety, depression, and challenges with thinking and memory. While it’s not considered a fatal disease, it is associated with significant morbidity and disability, and complications from PD can challenge vital activities like eating and sleeping.

Parkinson’s disease has become the fastest growing neurological disorder worldwide, with approximately one million people diagnosed in the U.S. The average age at diagnosis for people with PD is 60; as people live longer, the number of people living with PD is predicted to grow significantly over the coming decades. Beyond age, family history, exposure to some toxins, and being male are potential risk factors.

New Parkinson’s diagnoses every year

90,000

Source: Parkinson’s Foundation

How frequently someone new is diagnosed with Parkinson’s Disease in the U.S.

The prevalence of Parkinson’s disease in America is set to double by 2040:

diagram

Source: National Library of Medicine

There is no cure, but there are more and better ways to treat symptoms, including everything from aerobic exercise to medications and even surgeries. Nevertheless, Parkinson’s disease is a chronic, high-burden disease to live with, with uneven access to movement disorder specialists, treatment continuity, and affordable formulations. Hope and opportunity comes from greater awareness, which helps drive more scientific study and community support.

Accessibility trends

Parkinson’s Disease remains challenging to live with but accessibility to lifestyle enhancement is improving

Affordability

Improving
Parkinson’s care is costly, and treatment costs vary widely based on insurance design, drug formulation, and geography. Generic medicines play an important role in moderating costs for many foundational Parkinson’s therapies, helping improve affordability and long-term access. However, financial and insurance barriers continue to limit affordability, especially for those relying on fixed incomes or disability benefits.
Average annual cost for Parkinson’s Disease medication
$2500
Of people with Parkinson's in the U.S., medicare covers the care of approximately
90%

Availability

Stable
Most people with Parkinson’s do not see a movement‑disorder specialist and many are managed in general neurology or primary care, reflecting limited specialist capacity. Telehealth, e‑consults, and outreach clinics are starting to expand reach, but there’s still a continued need for investment to make multidisciplinary care truly accessible. For most commonly used medications, wholesale production and global distribution are relatively mature and stable
Number of Parkinson’s Disease patients in the U.S.
1 100 000
Proportion of PD patients who see a movement disorder specialist
9%
Median number of miles many PD patients travel to see a specialist
1
0
0

Innovation

Accelerating
After years of mainly symptomatic therapies, Parkinson’s research is now pushing into adaptive devices, biologics, gene‑ and cell‑based approaches, and disease‑modifying strategies. New technologies like adaptive deep brain stimulation (aDBS) have gained FDA approval and parallel advances in nanomedicine, gene therapy, and CRISPR‑based approaches are being explored as part of a new era in Parkinson’s neurological care.
Clinical trials currently in development globally for Parkinson’s disease
136+
Parkinson's DBS treatment video

Knowledge

Improving
Parkinson’s knowledge and support have grown through national organizations, awareness months, and structured care resources for patients and caregivers. However, there is still an associated stigma and gaps in understanding Parkinson’s which underscore that education and caregiver support must scale.
For patients with Parkinson’s Disease, suboptimal adherence is common and varies between
10% – 67%

Amneal’s commitment to the Parkinson’s community

Dedicating decades to innovation and support for the Parkinson’s community

For decades, Amneal has been committed to advancing care for people living with Parkinson’s disease, building a portfolio of treatments designed to meet patients’ evolving needs over time.

CREXONT® (carbidopa/levodopa) represents the latest innovation in that effort—an extended-release, dual-phase capsule engineered to deliver more sustained “Good On” time with fewer doses. For people navigating mobility challenges, slowness, or stiffness, this added duration may translate into greater ease, more independence, and more moments that feel like themselves again.

Patient
"The approval of CREXONT is a seminal moment in the treatment paradigm for Parkinson's disease. Amneal is so excited to introduce this meaningful new treatment for Parkinson's patients in the U.S. and soon internationally. We are committed to continuing to advance Parkinson's research and development as a leader in the space."
Joe Renda
Senior Vice President, Chief Commercial Officer – Specialty
Amneal has been dedicated to supporting the Parkinson’s community for more than 15 years
Patients in the United States who have been prescribed CREXONT
27,202+
Amount of insurance coverage we’ve been able to help expand for our innovative Parkinson’s treatments in the last year alone
>20%
Number of Amneal employees who walked in the Michael J. Fox Parkinson’s Unity Walk in 2024
150

We hosted a Lunch & Learn for our U.S. employees with Dr. Torres-Yaghi, MD, and Dr. Pagan, MD, two respected Movement Disorder Specialists from MedStar Georgetown University Hospital who shared valuable insights into Parkinson’s disease.

Amneal’s financial commitment to supporting patient assistance foundations in Parkinson's since 2025
$3.5M
Amneal SPARK program

Amneal SPARK program

Learn more

The information presented in this Accessibility Index is compiled from publicly available sources believed to be reliable at the time of publication. However, Amneal makes no representations or warranties, express or implied, regarding the accuracy, completeness, or timeliness of the data provided. The content is for informational purposes only and does not constitute professional advice or endorsement.

The views and opinions expressed in this index do not necessarily reflect those of Amneal, its affiliates, or its employees. Amneal disclaims any liability for any decisions made or actions taken based on the information contained herein.

This index is intended to support awareness and understanding of medicine accessibility and is not a substitute for professional consultation or regulatory guidance. Users are encouraged to verify information independently and consult appropriate experts before making decisions.

By using this site, you acknowledge and agree to these terms.